公开(公告)号：EP3065726A4

公开(公告)日：2017-06-21

申请号：EP14859445

申请日：2014-11-05

申请人： ULTRAGENYX PHARMACEUTICAL INC

发明人： JUNGLES STEVEN ,  CHAN YIUMO ,  KAKKIS EMIL

IPC分类号： A61K31/155 ,  C07C277/08

CPC分类号： C07C279/22 ,  C07C279/14 ,  C07C279/24 ,  C07D273/08 ,  C07D307/62 ,  C07H13/04 ,  C07H19/167

公开(公告)号：EP2659885B1

公开(公告)日：2016-11-09

申请号：EP13178966.1

申请日：2008-08-04

申请人： Biotron Limited

发明人： Ewart, Gary Dinneen ,  Luscombe, Carolyn Anne ,  Miller, Michelle

IPC分类号： A61K31/155 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/435 ,  A61P31/14 ,  A61K31/7064 ,  A61K31/7068 ,  A61K45/06 ,  A61K31/7056 ,  A61K38/21 ,  A61P1/16 ,  A61P31/12

CPC分类号： C07C279/22 ,  A61K31/155 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/435 ,  A61K31/4418 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07C311/08 ,  C07D213/69 ,  C07D231/12 ,  C07D307/54 ,  C07D333/24 ,  A61K2300/00

摘要： The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.

公开(公告)号：EP2200977B1

公开(公告)日：2016-11-09

申请号：EP08831237.6

申请日：2008-09-11

申请人： The Regents of the University of Michigan

发明人： GLICK, Gary D. ,  NEY, Gina

IPC分类号： C07C279/04 ,  C07C233/02 ,  A61P9/00 ,  A61P17/00 ,  A61P19/00 ,  A61K31/4164 ,  C07C279/22

CPC分类号： C07C279/22

公开(公告)号：EP2758369A1

公开(公告)日：2014-07-30

申请号：EP12781454.9

申请日：2012-09-21

申请人： Centre National de la Recherche Scientifique ,  Université de Strasbourg

发明人： RUAT, Martial ,  FAURE, Hélène ,  ROUDAUT, Hermine ,  HOCH, Lucile ,  SCHOENFELDER, Angèle ,  TADDEI, Maurizio ,  MANN, André

IPC分类号： C07C279/22 ,  A61K31/155

CPC分类号： C07C279/24 ,  C07C279/22 ,  G01N33/5011 ,  G01N33/5041 ,  G01N33/57492

摘要： The present invention relates to novel compounds having the following formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, for the treatment of neurodegenerative diseases, for the treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring, for the treatment of cerebrovascular accidents and cardiovascular accidents, for the treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof
in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The present invention also relates to pharmaceutical compositions comprising at least one compound having formula (I). The invention also relates to a method for radio-marking compounds having formula (I), the marked compounds, and the use of said compounds as research tools. Finally, the present invention also relates to a method for screening and/or identifying ligands in the Smoothened receptor (Smo) binding sites, methods for identifying agonists and antagonists of the Smoothened receptor, and a method for identifying cells.

公开(公告)号：EP2194976A4

公开(公告)日：2012-12-26

申请号：EP08782880

申请日：2008-08-04

申请人： BIOTRON LTD

发明人： EWART GARY DINNEEN ,  LUSCOMBE CAROLYN ANNE ,  MILLER MICHELLE

IPC分类号： A61K31/155 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/435 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K38/21 ,  A61K45/06 ,  A61P31/14

CPC分类号： C07C279/22 ,  A61K31/155 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/435 ,  A61K31/4418 ,  A61K31/7056 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7076 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07C311/08 ,  C07D213/69 ,  C07D231/12 ,  C07D307/54 ,  C07D333/24 ,  A61K2300/00

摘要： The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.

公开(公告)号：EP1942101A4

公开(公告)日：2010-08-25

申请号：EP06797138

申请日：2006-08-31

申请人： KISO YOSHIAKI

发明人： KISO YOSHIAKI ,  MIMOTO TSUTOMU ,  NOJIMA SATOSHI ,  KINOMURA NAOYA

IPC分类号： C07C279/22 ,  A61K31/41 ,  A61K31/4168 ,  A61K31/454 ,  A61K31/506 ,  A61P25/28 ,  A61P43/00 ,  C07D233/88 ,  C07D235/30 ,  C07D257/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

CPC分类号： C07D233/88 ,  C07C279/22 ,  C07D235/30 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

公开(公告)号：EP2200977A2

公开(公告)日：2010-06-30

申请号：EP08831237.6

申请日：2008-09-11

申请人： The Regents of the University of Michigan

发明人： GLICK, Gary D. ,  NEY, Gina

IPC分类号： C07C279/04 ,  C07C233/02

CPC分类号： C07C279/22

摘要： The present invention relates to a family of guanidine-based F1F0-ATPase inhibitors, e.g., mitochondrial F1F0-ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders.

公开(公告)号：EP2177505A1

公开(公告)日：2010-04-21

申请号：EP08792314.0

申请日：2008-08-07

申请人： Astellas Pharma Inc.

发明人： KINOYAMA, Isao ,  MIYAMOTO, Satoshi ,  MIYAZAKI, Takehiro ,  KOGANEMARU, Yohei ,  KAWAMOTO, Yuichiro ,  SHIRAISHI, Nobuyuki ,  HOSHII, Hiroaki ,  KURODA, Akio ,  YAMAZAKI, Mayako ,  YASUDA, Minoru ,  MIZUNO, Hiroaki

IPC分类号： C07C279/22 ,  A61K31/341 ,  A61K31/352 ,  A61K31/495 ,  A61P25/28 ,  A61P43/00 ,  C07D295/12 ,  C07D307/52 ,  C07D311/04

CPC分类号： C07D295/12 ,  C07C279/22 ,  C07C317/44 ,  C07C2601/02 ,  C07C2602/10 ,  C07C2602/12 ,  C07D213/56 ,  C07D213/61 ,  C07D213/64 ,  C07D215/12 ,  C07D231/12 ,  C07D239/26 ,  C07D241/12 ,  C07D261/08 ,  C07D277/30 ,  C07D295/155 ,  C07D307/52 ,  C07D307/54 ,  C07D309/04 ,  C07D311/04 ,  C07D311/58 ,  C07D313/08 ,  C07D319/18 ,  C07D333/24 ,  C07D333/54 ,  C07D333/56 ,  C07D335/06 ,  C07D405/04 ,  C07D407/04 ,  C07D409/04 ,  C07D471/04

摘要： An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT 5A receptor modulating action.
It was confirmed that a bicyclic acylguanidine derivative which has a characteristic structure that guanidine is bonded to one ring of a bicyclic structure such as chromene and dihydronaphthalene through a carbonyl group and a cyclic group is bonded on the other ring, has a potent 5-HT 5A receptor modulating action and an excellent pharmacological action based on this mechanism. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.

摘要翻译： 本发明的目的在于提供基于血清素5-HT5A受体调节作用的新型优异的痴呆症，精神分裂症等的治疗或预防剂。 已证实具有特征结构的双环酰基胍衍生物具有强效的5-HT5A，所述双环酰基胍衍生物具有特征结构，其中胍与色烯和二氢萘的双环结构的一个环经由羰基和环状基团键合， 受体调节作用和基于这种机制的优异药理作用。 本发明作为治疗或预防痴呆症，精神分裂症，双相性精神障碍或注意力缺陷多动症的优异药剂是有用的。

公开(公告)号：EP1236712B1

公开(公告)日：2008-08-06

申请号：EP00979071.8

申请日：2000-12-04

申请人： Ajinomoto Co., Inc.

发明人： SUGIKI, Masayuki, Pharmaceutical Research Lab. ,  SAGI, Kazuyuki, Pharmaceutical Research Lab. ,  FUJITA, Kohichi, Pharmaceutical Research Lab. ,  KAYAHARA, Takashi, Pharmaceutical Research Lab. ,  TAKEHANA, Shunji, Pharmaceutical Research Lab. ,  SAKURAI, Kuniya, Pharmaceutical Research Lab. ,  TASHIRO, Kazumi, Pharmaceutical Research Lab.

IPC分类号： C07C257/18 ,  C07C279/14 ,  C07C279/22 ,  C07D215/48 ,  C07D235/30 ,  C07D235/08 ,  C07D333/40 ,  C07D333/24 ,  C07D215/58 ,  C07D213/74 ,  C07D401/04 ,  C07D277/82 ,  C07D277/64 ,  C07D233/60 ,  C07D239/84

CPC分类号： C07D213/73 ,  C07C257/18 ,  C07C279/14 ,  C07C279/18 ,  C07C279/22 ,  C07C2601/04 ,  C07C2601/08 ,  C07D213/56 ,  C07D215/48 ,  C07D231/12 ,  C07D233/56 ,  C07D235/08 ,  C07D235/30 ,  C07D239/84 ,  C07D249/08 ,  C07D277/64 ,  C07D277/82 ,  C07D307/79 ,  C07D333/24 ,  C07D333/38 ,  C07D401/04

摘要： An amidinophenylpyruvic acid derivative represented by the following formula, its analogs and pharmaceutically acceptable salts thereof which have an excellent effect of inhibiting activated blood coagulation factor VII.

摘要翻译： 由下式表示的脒基丙酮酸衍生物，其类似物及其药学上可接受的盐，其具有优异的抑制活化血液凝固因子VII的作用。

公开(公告)号：EP1942101A1

公开(公告)日：2008-07-09

申请号：EP06797138.2

申请日：2006-08-31

申请人： Dainippon Sumitomo Pharma Co., Ltd. ,  Kiso, Yoshiaki

发明人： KISO, Yoshiaki ,  MIMOTO, Tsutomu ,  NOJIMA, Satoshi ,  KINOMURA, Naoya

IPC分类号： C07C279/22 ,  A61K31/41 ,  A61K31/4168 ,  A61K31/454 ,  A61K31/506 ,  A61P25/28 ,  A61P43/00 ,  C07D233/88 ,  C07D235/30 ,  C07D257/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

CPC分类号： C07D233/88 ,  C07C279/22 ,  C07D235/30 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

摘要： The present invention relates to a compound of the formula (1):

wherein R 1 is group of the formula (2):

(wherein X is nitrogen atom or C(R 5 ), Y is nitrogen atom or C(R 6 ), R 5 and R 6 are each independently hydrogen atom, etc.) etc., m is 1 to 6, L 1 is single bond, etc., R 2 is hydrogen atom, substituted or unsubstituted alkyl group, etc., R 3 is hydrogen atom, etc., L 2 is single bond, etc., R 4 is hydrogen atom, substituted or unsubstituted aryl group, etc., or pharmaceutically acceptable salt thereof, being useful for preventing or treating Alzheimer's disease.

摘要翻译： 本发明涉及式（1）的化合物：其中R 1为式（2）的基团：其中X为氮原子或C（R 5），Y为氮原子或C（R 6），R 5和R 6 各自独立地为氢原子等）等，m为1至6，L 1为单键等，R 2为氢原子，取代或未取代的烷基等，R 3为氢原子等，L 2为 单键等，R 4为氢原子，取代或未取代的芳基等，或其药学上可接受的盐，可用于预防或治疗阿尔茨海默病。